Arliene Ravelo - Concepedia

Author

Arliene Ravelo

University of Washington ORCID

Also Known As

A Ravelo, A. Ravelo, Arliene L Ravelo, Arliene Ravelo, Arliene Ravelo, MPH

128

Publications

1.1K

Citations

H-Index

Concepts

All Affiliations

University of Washington Vector Oncology (United States)The US Oncology Network Memorial Sloan Kettering Cancer Center Dana-Farber Cancer Institute

About

Arliene Ravelo is an author at University of Washington specializing in medicine, radiation oncology, and outcomes research.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	7	7	180
2	Health Sciences	3	3	334
3	Public Health	1	1	279
4	Health Policy	1	1	279
5	Immunology	1	1	36

Arliene Ravelo

Publications

937

Citations

H-Index

Page 1

	Year	Citations
Prevalence and Costs of Chronic Conditions in the VA Health Care System Wei Yu, Arliene Ravelo, Todd H. Wagner, Medical Care Research and Review Total CostHealth Care UsersDisease ManagementChronic Disease ManagementHealth Economics	2003	279
Health-Related Quality of Life in a Randomized Phase III Study of Bevacizumab, Temozolomide, and Radiotherapy in Newly Diagnosed Glioblastoma Roger Henriksson, Andrew Bottomley, Timothy F. Cloughesy, Journal of Clinical Oncology	2015	135
The relationships among age, chronic conditions, and healthcare costs. Wei Yu, Arliene Ravelo, Todd H. Wagner, PubMed	2004	60
Cost Analysis of Interventions for Antimuscarinic Refractory Patients With Overactive Bladder Jonathan H. Watanabe, Jonathan D. Campbell, Arliene Ravelo, Urology Antimuscarinic Refractory PatientsUrologyUrological ResearchVoiding DysfunctionOutcomes Research	2010	47
Overall survival in patients with glioblastoma before and after bevacizumab approval Derek R. Johnson, Antonio Omuro, Arliene Ravelo, Current Medical Research and Opinion	2017	42
Progression-free survival (PFS) and health-related quality of life (HRQoL) in AVAglio, a phase III study of bevacizumab (Bv), temozolomide (T), and radiotherapy (RT) in newly diagnosed glioblastoma (GBM). Roger Henriksson, Andrew Bottomley, Warren Mason, Journal of Clinical Oncology Progression-free SurvivalHealth-related QualityCancer ManagementImmunologyPharmacotherapy	2013	36
Cost of Disease Progression in Patients with Metastatic Breast, Lung, and Colorectal Cancer Nicole Engel-Nitz, Stacey DaCosta Byfield, Arliene Ravelo, The Oncologist	2019	36
Bevacizumab Treatment to Progression After Chemotherapy: Outcomes from a U.S. Community Practice Network Eric Nadler, Elaine Yu, Arliene Ravelo, The Oncologist Residual PfsAdvanced NsclcOncologyBevacizumab MonotherapyBevacizumab Treatment	2011	30
Projected Clinical, Resource Use, and Fiscal Impacts of Implementing Low-Dose Computed Tomography Lung Cancer Screening in Medicare Joshua A. Roth, Sean D. Sullivan, Bernardo H. L. Goulart, Journal of Oncology Practice	2015	29
The cost-effectiveness of alectinib in anaplastic lymphoma kinase-positive (ALK+) advanced NSCLC previously treated with crizotinib JJ Carlson, William J. Canestaro, Arliene Ravelo, Journal of Medical Economics	2017	25

Page 1